FOSTER CITY, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing a new class of cancer ...
Presentation to highlight WVE-007 (INHBE GalNAc-siRNA) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable ...
NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (TGTX), today announced the presentation of data highlighting BRIUMVI ® (ublituximab-xiiy), to be presented at the Americas Committee ...
Regeneron presents real-world data on EYLEA HD's effectiveness and economic benefits in treating retinal diseases at ARVO 2025. Regeneron Pharmaceuticals announced the upcoming presentation of data on ...
ROCKVILLE, Md. and BARCELONA, Spain, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing ...
Asianet Newsable on MSN
Theriva™ Biologics announces upcoming presentation of data from VCN-01 retinoblastoma phase 1 clinical trial at APAO 2026
Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results